Clinical Application of PET Imaging Targeting MSLN in Malignant Tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

Processing failed - manual review needed

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Each subject must meet all enrollment criteria to be eligible to participate in the study:

  1. The subject or his/her legal representative is able to sign and date the informed consent form;
  2. A commitment to comply with the research procedures and to cooperate in the implementation of the full research process;
  3. Adult patients or healthy volunteers (aged 18 or above) of either sex;
  4. Patients with clinically suspected or confirmed malignant tumors such as pancreatic cancer, ovarian cancer, or lung adenocarcinoma (supporting evidence includes serum-related tumor markers, imaging data such as ultrasound, CT, MRI, etc., and histological pathology examination, etc.) and in good general condition;
  5. Consistent with the results of specific laboratory tests;
  6. Females of childbearing potential who have been using contraception for at least one month prior to screening and who are committed to using contraception for the entire study period and until a specified time after the end of the study；
  7. Other set entry criteria.

Exclusion Criteria:

* All subjects who meet any of the exclusion criteria baseline will be excluded from the study:

  1. Those who are unable to complete a PET/MR or PET/CT examination (including inability to lie down, claustrophobia, radiophobia, etc.);
  2. Having other comorbidities;
  3. Patients with known hypersensitivity to MSLN antibody fragment developers or synthetic excipients; fasting blood glucose level greater than 11.0 mmol/L prior to 18F-FDG injection；
  4. Have a history of comorbid drug use;
  5. Patients considered by the investigator to have poor compliance;
  6. Patients during pregnancy or lactation;
  7. Persons with other factors that make participation in this test inappropriate.

Where it's running

• Wuhan Union Hospital, China
  Wuhan, Hubei, China Recruiting

Study contacts

• Study coordinator: Xiaoli Lan, PhD
• Email: lxl730724@hotmail.com
• Phone: 0086-027-83692633

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• 68Ga-SorB PET/CT imaging for solid tumors

  This study tests a new PET tracer called 68Ga-SorB to see if it can safely and accurately detect tumors in adults with melanoma, liver, lung, breast, pancreatic, ovarian cancer, or cholangiocarcinoma.

  Recruiting Peking University Third Hospital · Beijing, Beijing Municipality · NCT07760012

• Prehabilitation before high-risk cancer surgery

  This trial tests a multidisciplinary prehabilitation program to see if it helps adults with cancer recover better after major abdominal surgery.

  Recruiting Fox Chase Cancer Center · Philadelphia, Pennsylvania · NCT07638410

• CAIX-targeted 18F-T2 PET/CT imaging in solid tumors

  This study tests a CAIX-specific radioactive tracer to see if PET/CT can help visualize solid tumors and checks safety and radiation exposure in adults with certain cancers.

  Recruiting Peking University First Hospital · Beijing, Beijing Municipality · NCT07557225

• Comprehensive multi-omics and functional profiling to fully characterize tumors

  This project tests whether detailed multi-omics and functional testing of tumor samples can better characterize high-risk blood and solid cancers for patients at participating centers.

  Recruiting at 2 sites Azienda Ospedaliero-Universitaria di Parma · Palermo, Palermo and 1 other locations · NCT07403630

• Digital app to support oncologist‑initiated genetic testing

  This project tests a digital app (GA‑Mainstream) to help oncologists offer germline genetic testing to adults with breast, prostate, colon, or other GI cancers.

  Recruiting at 2 sites Unity Health Toronto · Toronto, Ontario and 1 other locations · NCT07387263

• SL-28 for Advanced Solid Tumours

  A new allogeneic cell therapy called SL-28 is being tested in adults with advanced solid tumors to see if it is safe and can help shrink tumors.

  Recruiting Phase 1/2 Second Life Therapeutics · Sydney, New South Wales and 2 other locations · NCT07341737

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.